PeerMMatasbZHarpazDShargorodskyM. Adiponectin as an Independent Predictor of Left Ventricular Hypertrophy in Nondiabetic Patients With Hypertension. Angiology. 2015;66(3):219–24.
2.
AthyrosVGTziomalosKKaragiannisAAnagnostisPMikhailidisDP. Should adipokines be considered in the choice of the treatment of obesity-related health problems?Curr Drug Targets. 2010;11(1):122–35.
3.
WolfsonNGavishDMatasZBoazMShargorodskyM. Relation of adiponectin to glucose tolerance status, adiposity, and cardiovascular risk factor load. Exp Diabetes Res. 2012;2012:250621.
4.
KatsikiNYovosJGGotzamani-PsarrakouAKaramitsosDT. Adipokines and vascular risk in type 2 diabetes mellitus. Angiology. 2011;62(8):601–4.
5.
ZhangBCLiuWJCheWLXuYW. Serum total adiponectin level and risk of cardiovascular disease in Han Chinese populations: a meta-analysis of 17 case-control studies. Clin Endocrinol (Oxf). 2012;77(3):370–8.
6.
AnagnostisPAthyrosVGKitaMKaragiannisA. Is there any association between adiponectin gene polymorphisms and cardiovascular disease?Angiology. 2013;64(4):253–6.
7.
RizkNMEl-MenyarAMareiI. Association of adiponectin gene polymorphism (+T45G) with acute coronary syndrome and circulating adiponectin levels. Angiology. 2013;64(4):257–65.
8.
MarneyAMBrownNJ. Aldosterone and end-organ damage. Clin Sci (Lond). 2007;113(6):267–78.
9.
KaragianisA. Treatment of primary aldosteronism: where are we now?Rev Endocr Metab Disord. 2011;12(1):15–20.
10.
NishizakaMKZamanMAGreenSARenfroeKYCalhounDA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004;109(23):2857–61.
11.
HaradaEYoshimuraMYasueH. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation. 2001;104(2):137–9.
12.
PierluissiJNavasFOAshcroftSJ. Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans. Diabetologia. 1986;29(2):119–21.
13.
CampionJMaestroBMataFDavilaNCarranzaMCCalleC. Inhibition by aldosterone of insulin receptor mRNA levels and insulin binding in U-937 human promonocytic cells. J Steroid BiochemMol Biol. 1999;70(4-6):211–8.
14.
CatenaCLapennaRBaroselliS. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91(9):3457–63.
15.
MilliezPGirerdXPlouinPFBlacherJSafarMEMouradJJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243–8.
16.
CalhounDAJonesDTextorS; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American heart association professional education committee of the council for high blood pressure research. Circulation. 2008;117(25):e510–26.
17.
AnagnostisPAthyrosVGTziomalosKKaragiannisAMikhailidisDP. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94(8):2692–701.
18.
GoodfriendTLKelleyDEGoodpasterBHWintersSJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res. 1999;7(4):355–62.
19.
Ehrhart-BornsteinMLamounier-ZepterVSchravenA. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA. 2003;100(24):14211–6.
20.
EssickEESamF. Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor. Int J Hypertens. 2011;2011:346985.
21.
RonconiVTurchiFBujalskaIJGiacchettiGBoscaroM. Adipose cell–adrenal interactions: current knowledge and future perspectives. Trends Endocrinol Metab. 2008;19(3):100–3.
22.
GiacchettiGFaloiaEMarinielloB. Overexpression of the renin–angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens. 2002;15(5):381–8.
DingGQinQHeN. Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma. J Mol Cell Cardiol. 2007;43(1):73–84.
25.
RossiGPSticchiDGiulianiL. Adiponectin receptor expression in the human adrenal cortex and aldosterone-producing adenomas. Int J Mol Med. 2006;17(6):975–80.
26.
LiPSunFCaoHM. Expression of adiponectin receptors in mouse adrenal glands and the adrenocortical Y-1 cell line: adiponectin regulates steroidogenesis. Biochem Biophys Res Commun. 2009;390(4):1208–13.
27.
IacobellisGPetramalaLCotestaD. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab. 2010;95(5):2391–8.
28.
FalloFDella MeaPSoninoN. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens. 2007;20(8):855–61.
29.
WilliamsTAMonticoneSUrbanetR. Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Mol Cell Endocrinol. 2012;355(1):162–8.
30.
RonconiVTurchiFRilliS. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. Nutr Metab Cardiovasc Dis. 2010;20(2):93–100.
31.
YanCJLiSMXiaoQ. Influence of serum adiponectin level and SNP +45 polymorphism of adiponectin gene on myocardial fibrosis. J Zhejiang Univ Sci B. 2013;14(8):721–8.
32.
ZhangYShaoLMaA. Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-β1/Smad signal pathway. Hypertens Res. 2014;37(1):43–9.
33.
TakagiHNiwaMMizunoYGotoSNUmemotoT; ALICE (All-literature investigation of cardiovascular evidence) group. Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome. J Am Soc Hypertens. 2013;7(3):229–35.
34.
PittBReichekNWillenbrockR. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831–8.
35.
FrantzEDCrespo-MascarenhasCBarreto-ViannaARAguilaMBMandarim-de-LacerdaCA. Renin–angiotensin system blockers protect pancreatic islets against diet-induced obesity and insulin resistance in mice. PLoS One. 2013;8(7):e67192.
36.
YilmazMISonmezACaglarK. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton). 2007;12(2):147–53.
37.
WangXLiuXZhanY. Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation. J Pharmacol Exp Ther. 2010;334(3):820–9.
38.
KatsikiNMikhailidisDPGotzamani-PsarrakouADidangelosTPYovosJGKaramitsosDT. Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptide Y levels in patients with type 2 diabetes mellitus: a pilot study. Open Cardiovasc Med J. 2011;5:136–47.
39.
KatsikiNMikhailidisDPGotzamani-PsarrakouAYovosJGKaramitsosD. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets. 2011;15(4):401–20.
40.
GengJZhaoZKangWWangWZhangYZhimingGE. Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats. Pharmacol Res. 2010;61(1):40–7.
41.
SenthilVChenSNTsyboulevaN. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res. 2005;97(3):285–92.
42.
NaguehSFLombardiRTanYWangJWillersonJTMarianAJ. Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study. Eur J Clin Invest. 2010;40(11):976–83.
43.
GeCJLuSZChenYDWuXFHuSJJiY. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels. 2008;23(2):91–5.
44.
FolkeringaRJde VosCPintoYM.No effect of rosuvastatin on left ventricular hypertrophy in patients with hypertension: a prospective randomised open-label study with blinded endpoint assessment. Int J Cardiol. 2010;145(1):156–8.
